- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03947034
Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX) (AmmoTOX)
April 4, 2023 updated by: Joe Elie Salem, Groupe Hospitalier Pitie-Salpetriere
Several drugs and chemotherapies seem to have an impact on the metabolic system.
This study investigates reports of metabolic toxicities such as hyperammonemia, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Several drugs and chemotherapies seem to have an impact on the metabolic system and are responsible of a wide range of metabolical side effects such as hyperammonemia.
Those are poorly described, due to the modification of the pharmacopeia, and the recent recognition of several of these adverse events.
This study investigates the main characteristics of patients affected by metabolic side effects imputed to drugs in particular hyperammonemia.
A causality assessment according to the WHO-UMC (World Health Organization - Uppsala Monitoring Center) is systematically applied.
Study Type
Observational
Enrollment (Actual)
2700
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75013
- AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients treated with a drug that could be reported in the WHO's pharmacovigilance database
Description
Inclusion Criteria:
- Case reported in the WHO's pharmacovigilance database till 01/05/2019
Exclusion Criteria:
- Chronology not compatible between the drug and the toxicity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Metabolic toxicity induced by drugs and chemotherapies
Case reported in the World Health Organization (WHO) of metabolic toxicities(such as hyperammonemia) of patient treated by a drug, with a chronology compatible with the drug toxicity
|
Drugs susceptible to induce metabolic toxicities such as hyperammonemia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic toxicities (such as hyperammnemia) of drugs Identification and report of cases of metabolic toxicities associated with drugs.
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Causality assessment of reported metabolic toxicities events according to the WHO system
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Description of the type of metabolic toxicity depending on the category of drug
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Description of the other immune related adverse events concomitant to the metabolic toxicity induced by drugs
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Description of the duration of treatment when the toxicity happens (role of cumulative dose)
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Description of the drug-drug interactions associated with adverse events
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Description of the pathologies (cancer) for which the incriminated drugs have been prescribed
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Description of the population of patients having hematological toxicity adverse event
Time Frame: to 01/05/2019
|
Case reported in the World Health Organization (WHO) database of individual safety case reports
|
to 01/05/2019
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2019
Primary Completion (Actual)
May 30, 2020
Study Completion (Actual)
April 4, 2023
Study Registration Dates
First Submitted
May 9, 2019
First Submitted That Met QC Criteria
May 9, 2019
First Posted (Actual)
May 13, 2019
Study Record Updates
Last Update Posted (Actual)
April 5, 2023
Last Update Submitted That Met QC Criteria
April 4, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIC1421-19-09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Disease
-
Yonsei UniversityUnknownCardiovascular Disease | Metabolic DiseaseKorea, Republic of
-
Clinical Nutrition Research Centre, SingaporeCompletedCardiovascular Disease | Metabolic Disease
-
San Diego State UniversityRecruitingBone Disease, MetabolicUnited States
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
The Hospital for Sick ChildrenRare Disease Foundation, Vancouver, CanadaCompleted
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
-
Shenzhen Center for Chronic Disease ControlCompletedNutrition Disorders | Genetic Predisposition to Disease | Metabolic DiseaseChina
-
National Institutes of Health Clinical Center (CC)CompletedVascular Diseases | Cancer | Metabolic Bone Disease | Inflammatory DiseaseUnited States
-
Istituto Ortopedico GaleazziUnknownPhysical Activity | Bone Disease, MetabolicItaly
-
Stanley Dudrick's Memorial HospitalCompletedMetabolic Bone DiseasePoland
Clinical Trials on Drugs inducing hyperammonemia
-
Groupe Hospitalier Pitie-SalpetriereCompletedEye Diseases | Uveitis | Uveitis Drug-Induced | Uvea--DiseasesFrance
-
University Hospital, GhentRecruitingHyperammonemic EncephalopathyBelgium
-
Groupe Hospitalier Pitie-SalpetriereCompletedLiver Diseases | Liver Failure | Liver Dysfunction | HepatotoxicityFrance
-
Groupe Hospitalier Pitie-SalpetriereCompletedMyocarditis | Myocardial Dysfunction | Myocardial FailureFrance
-
Groupe Hospitalier Pitie-SalpetriereCompletedAntiphospholipid Syndrome | Adverse Drug Event | Drug Toxicity | Immune DiseaseFrance
-
Groupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedHematological Abnormality | HematotoxicityFrance
-
Ding CongCompleted
-
University of FloridaCompletedHealthy | Musculoskeletal PainUnited States
-
University of FloridaCompletedMusculoskeletal Pain | Neck PainUnited States
-
Istituti Clinici Scientifici Maugeri SpAUniversity of BolognaCompleted